RESULTADOS MATERNOS E NEONATAIS E TEMPO DE ADMINISTRAÇÃO DO SULFATO DE MAGNÉSIO EM PACIENTES COM DOENÇA HIPERTENSIVA ESPECÍFICA DA GESTAÇÃO
DOI:
https://doi.org/10.63845/njbj8c72Palavras-chave:
Pré-eclampsia, Sulfato de magnésio, Resultados maternos e neonatais.Resumo
Introdução: A pré-eclâmpsia ocorre em 7-10% das gestações e representa a principal causa de mortalidade materna no mundo, sendo o sulfato de magnésio a droga mais eficaz na prevenção e controle das convulsões. Objetivo: Estimar associação entre resultados maternos e neonatais com a agilidade para o início da terapia com sulfato de magnésio e interrupção da gestação em pacientes com doença hipertensiva específica da gestação em um hospital público. Métodos: Foram avaliados 60 prontuários de gestantes com pré-eclampsia grave e eclampsia e de seus respectivos recém-nascidos, que receberam sulfato de magnésio. Foi utilizado o teste qui-quadrado (χ2), e estimado o Odds Ratio (OR) e respectivos intervalos de confiança. Resultados: O tempo decorrido da internação até o início da sulfatação maior que 1 hora e 30 minutos mostrou-se associado ao Apgar desfovorável, OR= 5,19 (IC 95% 1,07-38,99). O intervalo de tempo entre o início da sulfatação e a realização da cesariana acima de 2 horas e 45 minutos apresentou OR= 6,34 (IC 95% 2,07-21,06) de prolongar por mais que 6 horas a estabilização da PAS e PAD. O intervalo entre o início do sulfato de magnésio e o nascimento quando acima de 2 horas e 45 minutos apresentou OR= 5,79 (IC 95% 1,88-19,37) do recém-nascido receber alta após o quinto dia de internação. Conclusão: A precocidade na instalação da terapia com sulfato de magnésio e a agilidade na interrupção da gestação são importantes no sucesso do tratamento materno e fetal.
Referências
American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-31.
Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nphrol. 2019;15(5) 275-89. DOI: https://doi.org/10.1038/s41581-019-0119-6
McDonald SD, Lutsiv O, Dzaja N, Duley L. A systematic review of maternal and infant outcomes following magnesium sulfate for pre-eclampsia/eclampsia in real-world use. Int J Gynecol Obstet. 2012;118(2):90-6. DOI: https://doi.org/10.1016/j.ijgo.2012.01.028
WHO. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World Health Organization; 2011. Disponível em: http://apps.who.int/iris/bitstream/10665/44703/1/9789241548335_eng.pdf. Acesso em 20/02/2022.
Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7. DOI: https://doi.org/10.1016/j.ejogrb.2013.05.005
Brasil. Ministério da Saúde. Departamento de Informática do SUS. Tabnet. Estatísticas Vitais – mortalidade e nascidos vivos. Disponível em: htpp://www.da tasus.gov.br. Acesso em 20/05/2019.
Amaral LA, Wallace K, Owens M, LaMarca B. Pathophysiology and current clinical management of preeclampsia. Curr Hypertens Rep. 2017;19:61. DOI: https://doi.org/10.1007/s11906-017-0757-7
Oguntunde O, Charyeva Z, Cannon M, Sambisa W, Orobaton N, Kabo IA, et al. Factors influencing the use of magnesium sulphate in pre-eclampsia/eclampsia management in health facilities in Northern Nigeria: a mixed methods study. BMC Pregnancy Childbirth. 2015;15(1): 1-8. DOI: https://doi.org/10.1186/s12884-015-0554-8
Long Q, Oladapo OT, Leathersich S, Vogel JP, Carroli G, Lumbiganon P, et al. Clinical practice patterns on the use of magnesium sulphate for treatment of pre-eclampsia and eclampsia: a multi-country survey. Int J Obstet Gy. 2016;124(12):1883-90. DOI: https://doi.org/10.1111/1471-0528.14400
Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;(11):1-84. DOI: https://doi.org/10.1002/14651858.CD000025.pub2
Pascoal ACF, Katz L, Pinto MH, Santos CA, Braga LCO, Maia SB, et al. Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia. Medicine. 2019; 98(32):1-9. DOI: https://doi.org/10.1097/MD.0000000000016779
Vigil-De Gracia P, Ramirez R, Durán Y, Quintero A. Magnesium sulfate for 6 vs 24 hours post delivery in patients who received magnesium sulfate for less than 8 hours before birth: a randomized clinical trial. BMC Pregnancy Childbirth. 2017; 17(241):1-6. DOI: https://doi.org/10.1186/s12884-017-1424-3
Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth. 2013; 13(295):1-31. DOI: https://doi.org/10.1186/1471-2393-13-195
Gordon R, Magee LA, Payne B, Firoz T, Sawchuck D, Tu D, et al. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: A systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2): 154-63.
Anjum S, Goel N, Sharma R, Mohsin Z, Garg N. Maternal outcomes after 12 hours and 24 hours of magnesium sulfate therapy for eclampsia. Int J Gynecol Obstet. 2015;132(1):68-71. DOI: https://doi.org/10.1016/j.ijgo.2015.06.056
Peres G, Mariana M, Cairrão E. Pre-eclampsia and eclampsia: An update on the pharmacological treatment applied in Portugal. J Cardiovasc Dev Dis. 2018; 5(1):1-13. DOI: https://doi.org/10.3390/jcdd5010003
Abdul, MA, Nasir UI, Khan N, Yusuf MD. Low-dose magnesium sulphate in the control of eclamptic fits: a randomized controlled Trial. ArchGynecol Obstet. 2012;287(1):43-6. DOI: https://doi.org/10.1007/s00404-012-2523-z
Shepherd E, Salam RA, Manhas D, Synnes A, Middleton P, Makrides M, et al. Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis. Plos Med. 2019;16(12):1-37. DOI: https://doi.org/10.1371/journal.pmed.1002988
Khooshideh M, Ghaffarpour M, Bitarafan S. The comparison of anti-seizure and tocolytic effects of phenytoin and magnesium sulphate in the treatment of eclampsia and preeclampsia: A randomised clinical trial. Iran J Neurol. 2017;16(3):125-9.
Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev. 2010;(12):1-29. DOI: https://doi.org/10.1002/14651858.CD000127.pub2
Zuspan FP. Treatment of severe preeclampsia and eclampsia. Clin Obstet Gynecol. 1966;9(4):954-72. DOI: https://doi.org/10.1097/00003081-196612000-00010
The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo controlled trial. Lancet. 2002;359(9321):1877-90. DOI: https://doi.org/10.1016/S0140-6736(02)08778-0
De Melo BCP, Amorim MMR, Katz L. Perfil epidemiológico e evolução clínica pós-parto na pré-eclâmpsia grave. Rev Assoc Med Bras. 2009;55(2):175-80. DOI: https://doi.org/10.1590/S0104-42302009000200022
Fontenot MT, Lewis DF, Frederick JB, DeFranco EA, Groome LJ, Evans AT. A prospective randomized trial of magnesium sulfate in severe preeclampsia: Use of diuresis as a clinical parameter to determine the duration of post partum therapy. Am J Obstet Gynecol. 2005;192:1788-94. DOI: https://doi.org/10.1016/j.ajog.2004.12.056
Van DijkMG,Olavarrieta CD, Zuñiga PU. Use ofmagnesium sulfate for treatment of pre-eclampsia and eclampsia in Mexico. Int J Gynecol Obstet. 2013;121:110-4. DOI: https://doi.org/10.1016/j.ijgo.2012.11.015
Maia SB, Katz L, Neto CN. Abbreviated (12-hour) versus traditional (24-hour) post partum magnesium sulfate therapy in severepre-eclampsia. Int J Gynecol Obstet. 2014;126:260-4. DOI: https://doi.org/10.1016/j.ijgo.2014.03.024
Gordon R, Magee LA, Payne B, Firoz T, Sowchuck D, Tu D, et al. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-63. DOI: https://doi.org/10.1016/S1701-2163(15)30662-9
Jayanna K, Mony P, BM R, Thomas A, Gaikwad A, HL M, et al. Assessment of facility readiness and provider preparedness for dealing with post partum haemorrhage and pre-eclampsia/eclampsia in public and private health facilities of northern Karnataka, India: a cross-sectional study. BMC Pregnancy Childbirth. 2014;14:304. DOI: https://doi.org/10.1186/1471-2393-14-304
Bourret B, Compère V, Torre S, Azhougagh K, Provost D, Rachet B, et al. Magnesium sulfate in the prophylaxis of eclampsia: A retrospective study. Ann Fr Anesth et Reanim. 2012; 31:933–36. DOI: https://doi.org/10.1016/j.annfar.2012.09.004
McDermott M, Miller EC, Rundek T, Hurn PD, Bushnell CD. Preeclampsia. Stroke. 2018;49(3): 524–530. DOI: https://doi.org/10.1161/STROKEAHA.117.018416
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Arquivos Catarinenses de Medicina
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
